GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Cash Payments for Loans

Antibe Therapeutics (TSX:ATE) Cash Payments for Loans


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Cash Payments for Loans?

Cash Payments for Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Antibe Therapeutics (TSX:ATE) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer